A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(27 sites)
United States
HonorHealth Research Institute, Phoenix, Arizona The Angeles Clinic, Los Angeles, California Hoag Memorial Hospital, Newport Beach, California California Pacific Medical Center, San Francisco, California Sarah Cannon Research Institute, Denver, Colorado Yale University, New Haven, Connecticut Orlando Health, Orlando, Florida Emory University, Atlanta, Georgia OSF St Francis Medical Center, Peoria, Illinois Indiana University, Indianapolis, Indiana Dana Faber Cancer Institute, Boston, Massachusetts Karmanos Cancer Institute, Detroit, Michigan Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada Roswell Park Comprehensive Cancer Center, Buffalo, New York Columbia University Medical Center, New York, New York Weil Cornell University, New York, New York Sarah Cannon Research Institute - Oklahoma University, Oklahoma City, Oklahoma University of Pennsylvania, Philadelphia, Pennsylvania Sarah Cannon Research Institute - Thomas Jefferson University, Philadelphia, Pennsylvania Sarah Cannon Research Institute, Nashville, Tennessee MD Anderson, Houston, Texas NEXT Oncology, Irving, Texas NEXT Oncology, San Antonio, Texas START Mountain Region, West Valley City, Utah NEXT Oncology, Fairfax, Virginia Swedish Cancer Institute, Seattle, Washington University of Wisconsin, Madison, Wisconsin Last updated February 2026